Stocktoria
Orthofix Medical Inc. OFIX
Orthofix Medical Inc. (OFIX) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $822.3M at a -11.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -3.22 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.29 |
| Retained earnings / assets | -0.433 |
| EBIT / assets | -0.096 |
| Equity / liabilities | 1.123 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| OFIX | Orthofix Medical Inc. | 5/9 | 1.02 | — | +2.9% |
| ATEC | Alphatec Holdings, Inc. | 6/9 | -4.63 | — | +25% |
| IRTC | iRhythm Holdings, Inc. | 5/9 | 0.78 | — | +26.2% |
| INSP | Inspire Medical Systems, Inc. | 6/9 | 9.88 | 9.1 | +13.6% |
| NVCR | NovoCure Ltd | 3/9 | -2.29 | — | +8.3% |
| TNDM | TANDEM DIABETES CARE INC | 3/9 | -3.04 | — | +7.9% |
| UFPT | UFP TECHNOLOGIES INC | 7/9 | 6 | 28.7 | +19.5% |
About Orthofix Medical Inc.
Orthofix Medical Inc., together with its subsidiaries, operates as a medical technology company in the United States, Italy, the United Kingdom, France, Germany, Brazil, and internationally. It operates through two segments, Global Spine and Global Limb Reconstruction. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulation devices that enhance bone fusion; designs, develops, and markets a portfolio of spine fixation implant products for use throughout the spinal column; and offers bone graft substitutes, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers in various forms with supporting graft delivery solutions to treat various spinal, orthopedic, and dental conditions. This segment also designs, develops, and markets a portfolio of navigation technologies, including tracked surgical tools, intelligent software, and imaging equipment based on machine-vision and optical innovations; and 7D FLASH Navigation System, a navigation platform for spinal and cranial procedures. The Global Limb Reconstruction segment offers products and solutions for the underserved limb reconstruction market, including deformity correction, limb lengthening, complex fracture management, and limb preservation. This segment also designs, develops, and markets external and internal fixation limb reconstruction products that are coupled with enabling digital technologies to support the entire patient care continuum. It sells its products through distributors and sales representatives to hospitals, healthcare organizations, healthcare providers, ambulatory surgery centers, and out-patient hospitals. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in July 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.
FAQ
Is OFIX financially healthy?
Orthofix Medical Inc.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does OFIX pay a dividend?
No, Orthofix Medical Inc. does not currently pay a dividend.
How profitable is OFIX?
In FY2025, Orthofix Medical Inc. had a net margin of -11.2% and a return on equity of -20.5%.
Is OFIX overvalued or undervalued?
Orthofix Medical Inc. trades at about 80.0× trailing earnings — below its 10-year norm (10-year range 17.3×–310.8×, median 168.9×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for OFIX?
The average Wall-Street price target for Orthofix Medical Inc. is $15.00, about 44.2% above the recent price, from 4 analysts (consensus: buy).
Is OFIX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Orthofix Medical Inc.: a Piotroski F-score of 5/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.